CA
NZ
UK
AU
IND
US
The identified catalyst is theEarningsrelease and the higher outlook. Full-year sales growth of 72% to 75% replaces 55% to 60%, so the impliedRevenuebase rises materially. As general context, an upward revision to a growth outlook tends to lift estimates, and a sharp jump in …
No catalyst was identified in published coverage. Two searches, one for a company release or filing and one for wider coverage, found no results, trial data, financing, listing notice or analyst action dated November 9 or 10, 2026. The company did announce on October …
The identified catalyst is the results release and guidance.Gross Profitwas USD 12.1 million, a margin near 62%, and management raised 2026 revenue guidance to USD 68 million to USD 70 million from USD 62 million to USD 66 million, which implies growth of roughly …
No company release, filing or analyst action dated November 9 or 10, 2026 was identified in published coverage, so there is no catalyst identified in published coverage. The most recent identified company item is the Nasdaq notice dated July 14, 2026, which extended the …
No release, filing or analyst action dated November 9 or 10, 2026 was identified in published coverage, so there is no catalyst identified in published coverage. Earlier items provide context only. A notice for a June 5, 2026 extraordinary general meeting proposed selling ATA …
No release, filing or analyst action dated November 9 or 10, 2026 was identified in published coverage, so there is no catalyst identified in published coverage. The company announced that it would report third-quarter 2026 results on November 11, 2026, so the rally came …
No company release, filing or trial announcement dated November 9 or 10, 2026 was identified in published coverage, so the rationale is no catalyst identified in published coverage. Context from the prior week is relevant. The company reported results on November 5, 2026 with …
The relevant catalyst is the Phase 2 TibuSHIELD result for tibulizumab, also called ZB-106, in hidradenitis suppurativa. The 16-week study enrolled 247 patients. Lesion counts fell 56% and 58.1% in the two dose arms against 52.5% on placebo, and the primary and key secondary …
No company release or filing dated November 9 or 10, 2026 was identified in published coverage, so the rationale is no catalyst identified in published coverage. The most recent company news found is dated November 2, 2026: PMGC Holdings, trading as ELAB, signed aTrademarklicense …
The catalyst is the third-quarter 2026 release. Revenue of USD 8.6 million rose 895% year over year, and FY2026 guidance of USD 25.0 million to USD 27.0 million implies growth of 377% to 415% from USD 5.2 million in 2025. TotalBacklogwas USD 18.7 million, …
Please wait processing your request...